Supplementary Material



Supplementary figure 1: Flowchart showing the process of patient enrollment.

Supplementary table 1: Composition of the patient cohort.

Cancer	ICD	Patients	
Lung	C34	4,320	
Sarcoma	C40, C41, C47-C49	1,578	
Breast	C50	1,223	
Head and Neck	C01-C13, C30-C32	1,026	
Liver	C22	728	
Brain	C71	644	
Pancreas	C25	620	
Colon	C18	606	
Melanoma	C43	600	
Stomach	C16	545	

Esophagus	C15	408
Eye	C69	384
Rectum	C20	373
Kidney	C64, C65	308
Uterus	C53-C55	275
Testis	C62	249
Prostate	C61	236
Mesothelioma	C45	229
Skin	C44	217
Bladder	C67	166
Biliary tract	C24	163
Ovary	C56	152
Thyroid gland	C73	117
Small intestine	C17	90
Heart	C38	84
Rectosigmoid junction	C19	80
Gallbladder	C23	64
Anus	C21	48
Other endocrine gland	C75	34
Urethra	C68	33
Vulva	C51	29
Other digestive organs	C26	24
Thymus	C37	21
Adrenal gland	C74	17
Penis	C60	11
Ureter	C66	10
Female genital	C57	9
Central nervous system	C72	5



Slope between marker values and RC on internal dataset

Supplementary Figure 2: Replicability of the xAI approach on the external dataset. Axes indicate the (linearized) relationship between marker values and their xAI-assigned RCs for the Internal (x axis) and external (y axis) datatset. xAI finds the similar relationships in both datasets (r=0.9).



Supplementary Figure 3: Validation of xAI results with Cox regression models. The x axis shows the linearized relationships between marker values and RC according to xAI (similar to Supplementary Figure 2). The y axis shows the hazards of each marker according to a univariate cox regression model on the same dataset. The cox regression models strongly support the results captured by xAI. A: Internal dataset (Pearson's r = 0.93), B: External dataset (Pearson's r = 0.97).



Supplementary Figure 4: Contribution of clinical markers to the prediction of TTNT.

A: Marker risk contribution (RC) on the TTNT prediction. Each point represents one marker value for one patient versus the LRP-assigned RC (y-axis) to the patient's prognosis. Marker values are standardized.

B: The risk contribution of CRP depended on the value of other markers. The standardized CRP level and LRPassigned RC are shown for all patients in the left plot. Right three plots depict the patients for whom the three selected markers platelet count, urea nitrogen and AST were in the highest or lowest 10% quantile.



Supplementary Figure 5: Axes indicate how the (linearized) relationships between marker values and xAI-assigned RCs differ between patient subgroups that depend on other markers (high or low). Given the linearized relationship between a marker Y and the RC of Y, the label X->Y defines how this relationship changes between patient groups with high and low X. Even these higher order interactions between markers show similar patterns in the internal (x axis) and external (y axis) dataset (r=0.58).



Supplementary Figure 6: Complex interactions found by xAI can be validated with mixed-effects Cox proportional hazards models. Given the linearized relationship between a marker Y and the RC of Y, the label X->Y defines how this relationship changes between patient groups with high and low X. The effects captured by xAI (x axis) correspond strongly to the effects estimated by mixed-effects Cox proportional hazards models. **A**: Internal dataset (r=0.91). **B**: External dataset (r=0.69).



Supplementary Figure 7: Comparison of established prognostic scores with the LRP-assigned RC for OS. The x-axis depicts the value of the different scores. The y-axis indicates the RC. Comparison is shown for each marker and cancer type. Asterisks indicate if correlation was significant. *: p<0.001, **: p<0.001, **: p<0.001



Supplementary Figure 8: Cumulative relevance for neural network decision-making. A: OS, B: TTNT All markers are ranked according to the decreasing marker importance (MI) assigned by LRP across all patients (x axis). MI is corrected for missing values. Y-axis shows the cumulative MI. 90 % of all MI is assigned to 114 (TTNT: 115) key prognostic markers.



Supplementary Figure 9: Marker importance of diagnostic features. Markers are ordered from top to bottom according to decreasing importance across all patients. Points are measurements in individual patients. Risk contribution (RC) of markers in individual patients is shown on the x axis. RC indicates the contribution to a better (negative) or worse (positive) prognosis. Point color indicates high (red) or low (blue) marker value. **A:** Contribution to overall survival (OS). **B:** Contribution to time-to-next-treatment (TTNT).

Α	OS	В	TINT
Insertion, replacement and removal of ureteral stent-		Ascites-	•
Pain-	•	Aphagia and dysphagia -	
Abnormalities of breathing-		Abnormalities of breathing -	
Ascites -	•	Insertion, replacement and removal of ureteral stent-	
Secondary malignant neoplasm of respiratory and digestive organs -	••	Phlebilis and thrombophlebilis -	
Malaise and fatigue -		Secondary malignant neoplasm of respiratory and digestive organs	
Reconstruction of meninges-		Secondary malignant neoplasm of other and unspecified sites -	••••••••••••
Other operations on the retina-		Construction of treatment alds is cardiotherapy	
Secondary malignant peoplasm of other and unspecified sites	·	Consecution of realment aids in radiomerapy-	
Pleural effusion		Pleural effusion -	•
Irradiation planning for percutaneous irradiation and brachytherapy-		Benign prostatic hyperplasia -	· · · · · · · · · · · · · · · · · · ·
Construction of treatment aids in radiotherapy-	••	Malaise and fatigue	
Phlebitis and thrombophlebitis -	— <u> </u>	Radiation simulation for external irradiation and brachytherapy-	
Radiation simulation for external irradiation and brachytherapy-	•	Irradiation planning for percutaneous irradiation and brachytherapy-	
Chronic kidney disease (CKD)-	•————	Diagnostic tracheobronchoscopy -	
Aphagia and dysphagia -		Purpura and other hemorrhagic conditions -	<u> </u>
Excision of muscle, tendon and fascia-	- <u>_</u>	Angina pectoris -	
Purpura and other hemorrhagic conditions -		Intravenous anesthetics -	•
Type 2 diabetes mellitus-		Type 2 diabetes mellitus -	
Other diseases of billary tract-	••	Nonrheumatic aortic valve disorders -	•
Alconor related disorders		Excision of muscle, tendon and fascia-	
Opening the skull via the calvarium		Enlarged lumph podes	
Preumonia		Other operations on the ratios	·
Fibrosis and cirrhosis of liver-		Opening the skull via the calvarium-	
Diseases of vocal cords and larynx-	••	Pharyngeal biopsy without incision -	· · · ·
Other bacterial agents -		Other disorders of urinary system-	• ••
Nonrheumatic aortic valve disorders-	•	Other aplastic anemias and other bone marrow failure syndromes -	•••——————————••
Fluorescence-assisted therapy-		Iron deficiency anemia -	•••••
Radical excision of diseased dermal tissue -	•	Secondary and unspecified malignant neoplasm of lymph nodes -	••••
Respiratory failure-	•	Anemia in chronic diseases -	•
Streptococcus, Staphylococcus, and Enterococcus-	•	Microsurgical technique -	
Abdominal and pelvic pain-	·	Destruction of diseased retina and choroidea tissue-	· · · · · · ·
Diagnostic tracheobronchoscopy-		Monitoring of cardiovascular and respiratory systems -	
Excision and destruction of diseased intracranial tissue-		Excision and destruction of diseased intracranial tissue -	
Gastro-esophageal reflux disease -	•	Diseases of vocal corts and larvay	
Atrial fibrillation and flutter-	••• •	Reconstruction of meninges -	
Monitoring of cardiovascular and respiratory systems-	· ·	Diagnostic oesophagoscopy-	· · · · · · · · · · · · · · · · · · ·
Destruction of diseased retina and choroidea tissue-	•••	Abdominal and pelvic pain -	•
Intravenous anesthetics -		Fibrosis and cirrhosis of liver-	· • • • • • • • • • • • • • • • • • • •
Disorders of mineral metabolism-	••	Intraoperative neurophysiological monitoring-	
Microsurgical technique -		Gastro-esophageal reflux disease -	•••••••••••••••••
Epilepsy and recurrent selzures -	•••••	Other diseases of billary tract-	•———————••
Pharyngeal biopsy without incision -		Reoperation -	• • • • • • • • •
High voltage radiotherapy-		Insertion and replacement of catheter in central nervous system vessels -	• ==== [] ==• •
Biopsy without incision on mouth and oral cavity	··	Chronic ischemic heart disease	· •••••
Diagnostic pharyngoscopy		Laparotomy -	
Symptoms and signs concerning lood and huid imake		Simple endotractieal intobation-	
Laparotomy -		Streptococcus, Staphylococcus, and Enterococcus.	
Chronic ischemic heart disease	• • •=== 11 === •	Pneumonia	······································
Other disorders of urinary system-	· •	Fever-	• • • • •
Nausea and vomiting-		Other coagulation defects -	•• •• •
Abnormalities of galt and mobility -	• [] • •	Diagnostic pharyngoscopy-	• ••• •• •
Iron deficiency anemia-	•	Sleep disorders-	•••
Other disorders of fluid, electrolyte and acid-base balance-		Other disorders of fluid, electrolyte and acid-base balance-	
Diagnostic oesophagoscopy-	·	Biopsy without incision on mouth and oral cavity-	•••••
Anemia in chronic diseases	• ••• ••• •	Symptoms and signs concerning food and fluid intake	
Other blood vessel operations-		Transarterial left heart cardiac catheterization	
Essential (primary) hypertension-		Epliepsy and recurrent selzures-	• • • • • • • • • •
Sieep disorders -	• • • • • • • • • • • • • • • • • • •	Nausea and Vomiting -	
Angina pectors		Essential (orimary) hypertension -	
Incisional biopsy of digestive organs and peritoneum	••••	Alcohol related disorders	
Overweight and obesity		Other anemias-	•••
Diagnostic laryngoscopy -		Respiratory failure -	••
Simple endotracheal intubation -	••• [] ••• ••	Neutropenia -	• • • • • • • • • • • • • • • • • • • •
Disorders of lipoprotein metabolism and other lipidemias-	• • •	Atherosclerosis -	••
	-0.1 0.0 0.1 0.2		-0.1 0.0 0.1 0.2
	Risk Contribution (RC)		Risk contribution (RC)

Supplementary Figure 10: ICD (black) and OPS codes (blue) with the highest assigned RC. A: Contribution to overall survival (OS). B: Contribution to time-to-next-treatment (TTNT).



Supplementary Figure 11: The relationship between mean marker importance (MI) of selected markers and cancer entities for TTNT. The x axis shows the MI on a logarithmic scale. For each marker, the three cancer entities with the highest marker MI are annotated. Body composition markers: Abdominal volumes of visceral adipose tissue (VAT), total adipose tissue (TAT), subcutaneous adipose tissue (SAT), intermuscular adipose tissue (IMAT), muscle, bone. ECOG PS had the highest MI in pancreatic, prostate, and liver cancers, whereas fT3 was particularly important for thyroid, testicular, and brain cancers.



Supplementary Figure 12: xKM curves show the progress of marker contribution for the prediction of overall survival (OS) for tumor specific markers along disease progression. Black lines represent Kaplan-Meier plots, while the colored lines visualize the change in marker importance (MI) for patients with different survival times. MI lines are scaled between zero and one. Only deceased patients were included in this analysis.



Supplementary Figure 13: Explainable Kaplan-Meier (xKM) plots depicting the importance of diagnostic markers for TTNT during disease progression. Black lines represent Kaplan-Meier plots, while the colored lines visualize the change in marker importance (MI) for patients with different survival times. MI lines are scaled between zero and one. Only deceased patients were included in this analysis.



Supplementary Figure 14: xKM curves show the progress of marker contribution for the prediction of time-to-nexttreatment (TTNT) for tumor specific markers along disease progression. Explainable Kaplan-Meier (xKM) plots depicting the importance of diagnostic markers during disease progression. Black lines represent Kaplan-Meier plots, while the colored lines visualize the change in marker importance (MI) for patients with different survival times. MI lines are scaled between zero and one. Only deceased patients were included in this analysis.